CA3242316A1 - Pyrazine compounds as inhibitors of flt3 - Google Patents

Pyrazine compounds as inhibitors of flt3

Info

Publication number
CA3242316A1
CA3242316A1 CA3242316A CA3242316A CA3242316A1 CA 3242316 A1 CA3242316 A1 CA 3242316A1 CA 3242316 A CA3242316 A CA 3242316A CA 3242316 A CA3242316 A CA 3242316A CA 3242316 A1 CA3242316 A1 CA 3242316A1
Authority
CA
Canada
Prior art keywords
compounds used
flt3 inhibitors
pyrazine compounds
pyrazine
flt3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242316A
Other languages
English (en)
French (fr)
Inventor
David Sperandio
Thomas Butler
Thorsten A. Kirschberg
Xiaodong Wang
Nan-Horng Lin
Solomon B. Ungashe
Neil Howard Squires
Ravindra B. Upasani
Thu Phan
James T. Palmer
Amna Trinity-Turjuman Adam
Yongli Su
Original Assignee
Biomea Fusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/040953 external-priority patent/WO2023027966A1/en
Application filed by Biomea Fusion Inc filed Critical Biomea Fusion Inc
Publication of CA3242316A1 publication Critical patent/CA3242316A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3242316A 2021-12-30 2022-12-29 Pyrazine compounds as inhibitors of flt3 Pending CA3242316A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163295494P 2021-12-30 2021-12-30
US63/295,494 2021-12-30
US202263316939P 2022-03-04 2022-03-04
US63/316,939 2022-03-04
US202263364860P 2022-05-17 2022-05-17
US63/364,860 2022-05-17
PCT/US2022/040953 WO2023027966A1 (en) 2021-08-24 2022-08-19 Pyrazine compounds as irreversible inhibitors of flt3
USPCT/US2022/040953 2022-08-19
US202263386772P 2022-12-09 2022-12-09
US63/386,772 2022-12-09
PCT/US2022/054270 WO2023129667A1 (en) 2021-12-30 2022-12-29 Pyrazine compounds as inhibitors of flt3

Publications (1)

Publication Number Publication Date
CA3242316A1 true CA3242316A1 (en) 2023-07-06

Family

ID=85225088

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242316A Pending CA3242316A1 (en) 2021-12-30 2022-12-29 Pyrazine compounds as inhibitors of flt3

Country Status (11)

Country Link
US (2) US11945785B2 (https=)
EP (1) EP4370506A1 (https=)
JP (1) JP2025502748A (https=)
KR (1) KR20240128987A (https=)
AU (1) AU2022426699A1 (https=)
CA (1) CA3242316A1 (https=)
IL (1) IL313670A (https=)
MX (1) MX2024008057A (https=)
PE (1) PE20242008A1 (https=)
TW (1) TW202340177A (https=)
WO (1) WO2023129667A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023225005A1 (en) * 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
JP2002309116A (ja) 2001-04-09 2002-10-23 Fuji Photo Film Co Ltd アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
JP4406515B2 (ja) 2001-04-09 2010-01-27 富士フイルム株式会社 アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
KR100601775B1 (ko) 2001-04-09 2006-07-19 후지 샤신 필름 가부시기가이샤 화상 형성용 착색 조성물 및 칼라 화상의 내오존성 개선방법
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP2003292859A (ja) 2002-01-30 2003-10-15 Fuji Photo Film Co Ltd インク組成物、インクジェット記録方法
JP3844338B2 (ja) 2002-02-01 2006-11-08 富士写真フイルム株式会社 インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004059687A (ja) 2002-07-26 2004-02-26 Fuji Photo Film Co Ltd 着色組成物、インクジェット記録用インク、インクジェット記録方法、感熱記録材料、カラートナー、およびカラーフィルター
JP4213922B2 (ja) 2002-08-12 2009-01-28 富士フイルム株式会社 インクジェット記録用インク及びインクセット、並びにインクジェット記録方法
JP2004083610A (ja) 2002-08-22 2004-03-18 Fuji Photo Film Co Ltd インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004099802A (ja) 2002-09-11 2004-04-02 Fuji Photo Film Co Ltd 画像形成用着色組成物、インクジェット記録用インクおよびインクジェット記録方法
JP4895341B2 (ja) 2004-07-08 2012-03-14 富士フイルム株式会社 アゾ色素、インクジェット記録用インク、感熱記録材料、カラートナー、カラーフィルター、インクジェット記録方法、インクカートリッジ及びインクジェットプリンター
JP5241513B2 (ja) 2006-01-26 2013-07-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノクロトニルアミノ置換キナゾリン誘導体の合成方法
JP2007203642A (ja) 2006-02-02 2007-08-16 Fujifilm Corp インクジェット記録用セット、及びインクジェット記録方法
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
US7741385B2 (en) 2006-10-31 2010-06-22 Hewlett-Packard Development Company, L.P. Ozone stable ink-jet inks
JP2009139810A (ja) 2007-12-10 2009-06-25 Konica Minolta Business Technologies Inc 電子写真用トナー
SI2428508T1 (sl) 2009-05-08 2016-04-29 Astellas Pharma Inc. Diamino heterociklična karboksamidna spojina
US8722930B2 (en) 2009-05-18 2014-05-13 Orion Corporation Protease inhibitors
AR078173A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso
WO2012002577A1 (ja) 2010-06-30 2012-01-05 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
EP2635556B1 (en) 2010-11-01 2017-06-21 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as syk modulators
DK2799431T3 (en) 2011-12-28 2018-03-26 Fujifilm Corp Hitherto unknown nicotinamide derivatives or salts thereof
PL2805940T3 (pl) 2012-01-17 2017-06-30 Astellas Pharma Inc. Związek pirazynokarboksyamidowy
EP2828259B1 (en) 2012-03-22 2018-08-08 Oscotec, Inc. Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
CN103732575A (zh) 2012-07-20 2014-04-16 中国人民解放军军事医学科学院毒物药物研究所 间二芳基苯胺类或吡啶胺类化合物、其制备方法及医药用途
CN105683167B (zh) 2013-10-16 2018-10-23 富士胶片株式会社 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
WO2015062929A1 (en) 2013-10-29 2015-05-07 Dystar Colours Distribution Gmbh Acid dyes, process for the production thereof and their use
EP2868710A1 (en) 2013-10-29 2015-05-06 DyStar Colours Distribution GmbH Metal free acid dyes, process for the production thereof and their use
EP2868709A1 (en) 2013-10-29 2015-05-06 DyStar Colours Distribution GmbH Metal free acid dyes, process for the production thereof and their use
US20200332369A1 (en) 2014-01-27 2020-10-22 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
CA2938818C (en) 2014-02-04 2023-03-07 Astellas Pharma Inc. Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP3150206A1 (en) 2014-05-28 2017-04-05 Astellas Pharma Inc. Medicinal composition comprising pyrazine carboxamide compound as active ingredient
JP6665154B2 (ja) 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体及びその薬学的使用
KR20170032244A (ko) 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN105439879B (zh) 2014-08-07 2018-08-10 天津法莫西医药科技有限公司 一种反式-4-二甲胺基巴豆酸盐酸盐的制备方法
WO2016023217A1 (zh) 2014-08-15 2016-02-18 安润医药科技（苏州）有限公司 喹唑啉衍生物、其制备方法、药物组合物和应用
WO2016027904A1 (ja) 2014-08-22 2016-02-25 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
ES2834618T3 (es) 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6
WO2016121777A1 (ja) 2015-01-28 2016-08-04 アステラス製薬株式会社 ピラジンカルボキサミド化合物の製造方法及びその合成中間体
EP3290036A4 (en) 2015-04-27 2019-01-02 Astellas Pharma Inc. Stabilized pharmaceutical composition
JP2018104290A (ja) 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN106267234B (zh) 2015-06-26 2020-04-10 上海市计划生育科学研究所 含有非核苷类逆转录酶抑制剂的阴道环及其制备方法
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
FI3318259T3 (fi) 2015-07-03 2023-03-20 Astellas Pharma Inc Stabiili farmaseuttinen koostumus annettavaksi suun kautta
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
CN106588943B (zh) 2015-10-19 2018-10-16 广东东阳光药业有限公司 一种egfr抑制剂的盐、晶型及其用途
ES2894691T3 (es) 2015-11-04 2022-02-15 Astellas Pharma Inc Composición farmacéutica para propósitos de inmunoterapia y/o inmunoestimulación que contiene compuesto heterocíclico de diamino-carboxamida como principio activo
CN108778260A (zh) 2015-11-11 2018-11-09 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
JP6921818B2 (ja) 2015-11-14 2021-08-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
WO2017083789A1 (en) 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
JP2019014653A (ja) 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
JP2019512495A (ja) 2016-03-29 2019-05-16 アステラス製薬株式会社 急性骨髄性白血病の治療のための併用療法
CN109562176A (zh) 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
WO2017218365A1 (en) 2016-06-16 2017-12-21 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
CN106083821B (zh) 2016-06-22 2019-01-11 上海皓元生物医药科技有限公司 一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法
HUE059242T2 (hu) 2016-07-29 2022-11-28 Rapt Therapeutics Inc Azetidin-származékok mint kemokin receptor modulátorok és felhasználásuk
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
US10111882B2 (en) 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors
US11672801B2 (en) 2016-10-19 2023-06-13 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
JPWO2018079570A1 (ja) 2016-10-26 2019-09-19 アステラス製薬株式会社 安定な医薬組成物
CN106589055B (zh) 2016-11-03 2020-07-28 清华大学 取代的细胞酰二肽类化合物及其制备方法和用途
AR110273A1 (es) 2016-11-30 2019-03-13 Pharmacyclics Llc Inhibidores de tirosina cinasa de bruton
CN108419436B (zh) 2016-12-09 2021-05-04 深圳市塔吉瑞生物医药有限公司 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US20180344702A1 (en) 2017-02-21 2018-12-06 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies
GB201704267D0 (en) 2017-03-17 2017-05-03 Genome Res Ltd Novel biomarker
WO2018175251A1 (en) 2017-03-20 2018-09-27 Celcuity Llc Methods of measuring signaling pathway activity for selection of therapeutic agents
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
CA3052543A1 (en) 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
WO2018200465A1 (en) 2017-04-24 2018-11-01 Ohio State Innovation Foundation Recombinant egfl7, egfl7 antibodies, and uses thereof
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
CN118772278A (zh) 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
WO2019012328A1 (en) 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
CN109251182A (zh) 2017-07-13 2019-01-22 广东东阳光药业有限公司 取代脲衍生物的盐及其在药物中的应用
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
JP2020535173A (ja) 2017-09-27 2020-12-03 エイアイ・セラピューティクス・インコーポレーテッド Ｈｓｐ９０阻害剤に関係する治療方法
CA3019207A1 (en) 2017-09-28 2019-03-28 The Governing Council Of The University Of Toronto Methods and compositions for inhibiting mutant egfr signaling
IL273824B2 (en) 2017-10-18 2024-07-01 Epizyme Inc Methods for using EHMT2 inhibitors in the treatment or prevention of blood disorders
JP6915076B2 (ja) 2017-10-24 2021-08-04 京セラ株式会社 複合基板、およびそれを用いた弾性波素子
EP3700516B1 (en) 2017-10-27 2024-01-24 Sonic Master Limited Inhibitors of dux4 induction for regulation of muscle function
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
GB201802307D0 (en) 2018-02-13 2018-03-28 Vib Vzw CD36 antagonists for use in melanoma treatment
WO2019178267A2 (en) 2018-03-13 2019-09-19 University Of Iowa Research Foundation Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
CN108392634A (zh) 2018-03-28 2018-08-14 清华大学 B7s1抑制剂在制备肝癌药物中的用途
WO2019184966A1 (zh) 2018-03-28 2019-10-03 深圳市塔吉瑞生物医药有限公司 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
WO2019197605A2 (en) 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
WO2019245269A1 (ko) 2018-06-18 2019-12-26 연세대학교 산학협력단 Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물
EA202190181A1 (ru) 2018-07-04 2021-05-27 Сайтоиммьюн Терапьютикс, Инк. Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US12083136B2 (en) 2018-07-31 2024-09-10 Ascentage Pharma (Suzhou) Co., Ltd Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
KR20200022712A (ko) 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP7201800B2 (ja) 2018-09-30 2023-01-10 メッドシャイン ディスカバリー インコーポレイテッド Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物
TW202027749A (zh) 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑
WO2020090970A1 (ja) 2018-10-31 2020-05-07 富士フイルム株式会社 抗腫瘍剤を含む医薬組成物
JPWO2020090968A1 (ja) 2018-10-31 2021-09-16 富士フイルム株式会社 抗腫瘍剤を含む造粒物
EP3875089A4 (en) 2018-10-31 2021-12-22 FUJIFILM Corporation TABLET CONTAINING AN ANTI-TUMOR AGENT
JPWO2020090969A1 (ja) 2018-10-31 2021-09-16 富士フイルム株式会社 抗腫瘍剤を含む医薬組成物の包装体
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
CN113677346A (zh) 2018-11-01 2021-11-19 希洛斯医药品股份有限公司 周期蛋白依赖性激酶7(cdk7)的抑制剂
WO2020118168A1 (en) 2018-12-07 2020-06-11 Cornell University Methods for detecting acute myeloid leukemia
US20200208114A1 (en) 2018-12-10 2020-07-02 The Broad Institute, Inc. Taxonomy and use of bone marrow stromal cell
WO2020122816A1 (en) 2018-12-12 2020-06-18 Agency For Science, Technology And Research Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
KR102230721B1 (ko) 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
WO2020172618A2 (en) 2019-02-21 2020-08-27 Bambu Vault Llc Remotely triggered therapy
WO2020171649A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
PH12021551985A1 (en) 2019-02-22 2022-08-22 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
US12472175B2 (en) 2019-02-26 2025-11-18 Oregon Health & Science University Methods of treating venetoclax-resistant acute myeloid leukemia
TW202045174A (zh) 2019-02-28 2020-12-16 日商富士軟片股份有限公司 組合醫藥
JP7455810B2 (ja) 2019-03-13 2024-03-26 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020204142A1 (ja) 2019-04-03 2020-10-08 アステラス製薬株式会社 医薬組成物
EP3955928A4 (en) 2019-04-17 2023-05-31 Board of Regents, The University of Texas System COMPOUNDS HAVING ANTITUMORIC ACTIVITY AGAINST CANCER CELLS WITH TYROSINE KINAS INHIBITOR-RESISTANT EGFR MUTATIONS
SG11202111120VA (en) 2019-04-17 2021-11-29 Univ Texas Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
WO2020219890A1 (en) 2019-04-25 2020-10-29 Ocular Therapeutix, Inc. Ocular hydrogel tyrosine kinase inhibitor implants
EP3965896A4 (en) 2019-05-09 2023-01-25 The United States Government as Represented by the Department of Veterans Affairs COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
BR112021025537A2 (pt) 2019-06-20 2022-03-03 Celgene Quanticel Res Inc Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
WO2021011871A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
WO2021030642A1 (en) 2019-08-14 2021-02-18 Memorial Sloan Kettering Cancer Center Methods of treating p53 mutant cancers using ogdh inhibitors cross-reference to related applications
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GEP20247688B (en) 2019-09-12 2024-11-11 Orion Corp Pyridine oxynitride, preparation method therefor and use thereof
WO2021076985A1 (en) 2019-10-16 2021-04-22 University Of Virginia Patent Foundation Ceramide ratios as predictive and therapeutic biomarkers for leukemias
AU2020370110A1 (en) 2019-10-21 2022-05-26 Rhizen Pharmaceuticals Ag Compositions comprising a DHODH inhibitor for the treatment of acute myeloid leukemia
CN112704679B (zh) 2019-10-24 2023-06-06 沈阳药科大学 含高三尖杉酯碱的药物组合物及其应用
CN114901284A (zh) 2019-10-29 2022-08-12 希洛斯医药品股份有限公司 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
JP2022554346A (ja) 2019-11-05 2022-12-28 セルジーン コーポレーション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法
WO2021092543A1 (en) 2019-11-08 2021-05-14 University Of Virginia Patent Foundation Ceramide analog saclac modulates sphingolipid levels and mcl-1 splicing to induce apoptosis in acute myeloid leukemia
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021094827A1 (en) 2019-11-11 2021-05-20 Race Oncology Ltd. Use of bisantrene to treat measurable residual disease in acute myeloid leukemia
CN115151534B (zh) 2020-02-14 2024-02-06 南京药石科技股份有限公司 白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法
WO2021180008A1 (zh) 2020-03-11 2021-09-16 暨南大学 含脲结构的三芳环化合物及其应用
CN111269149B (zh) 2020-04-08 2022-04-15 南京优氟医药科技有限公司 一种5-(3,3-二甲基胍基)-2-氧代戊酸的生产工艺
CN111358952B (zh) 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
CN111558044B (zh) 2020-06-01 2022-02-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种包含舒尼替尼的药物组合物及其制剂和应用
CN111808821B (zh) 2020-06-24 2022-06-14 南方医科大学珠江医院 Flt3-nkg2d双靶点car-t的构建与制备
WO2022009235A1 (en) 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
CN111760024B (zh) 2020-07-24 2021-12-28 中国药科大学 一种渗透增强型金纳米簇载药靶向制剂及其制法和应用
WO2022132936A1 (en) 2020-12-15 2022-06-23 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
KR102231446B1 (ko) 2021-01-21 2021-03-24 (주) 와이디생명과학 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
CN116847845A (zh) 2021-02-12 2023-10-03 公益财团法人癌研究会 吉瑞替尼对于各种突变体的应用
CN115429805A (zh) 2021-06-01 2022-12-06 上海交通大学医学院附属瑞金医院 一种抗flt3-itd耐药突变型急性髓系白血病药物
TW202317561A (zh) 2021-07-01 2023-05-01 美商羅曼德生物治療公司 作為治療劑的具有１ｈ—吡唑并［４，３—ｃ］吡啶—６—胺基的化合物
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023043630A1 (en) 2021-09-16 2023-03-23 Lomond Therapeutics, Inc. Compounds having n-arylpyrimidin-2-amine derivatives as therapeutic agents
KR20240069783A (ko) 2021-09-24 2024-05-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 작용제의 선택적 전달을 위한 전구약물로서의 고리형 퍼옥시드
CN113861179A (zh) 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用
WO2023116888A1 (zh) 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
WO2023150601A2 (en) 2022-02-02 2023-08-10 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN115710281B (zh) 2022-11-14 2024-05-17 南京中医药大学 一种异噁唑并[5,4-b]吡啶类FLT3抑制剂及其制备方法与用途

Also Published As

Publication number Publication date
EP4370506A1 (en) 2024-05-22
US20240262795A1 (en) 2024-08-08
JP2025502748A (ja) 2025-01-28
AU2022426699A1 (en) 2024-07-11
US20230339867A1 (en) 2023-10-26
US11945785B2 (en) 2024-04-02
PE20242008A1 (es) 2024-10-03
KR20240128987A (ko) 2024-08-27
IL313670A (en) 2024-08-01
TW202340177A (zh) 2023-10-16
WO2023129667A1 (en) 2023-07-06
MX2024008057A (es) 2024-08-28

Similar Documents

Publication Publication Date Title
CA3242316A1 (en) Pyrazine compounds as inhibitors of flt3
DK3870574T3 (da) Aminopyridin/pyrazinderivater som ctps1-inhibitorer
MX374439B (es) Compuesto de piridona como inhibidor de c-met
EP3478687A4 (en) PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR
ZA201804870B (en) Acid addition salts of piperazine derivatives
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
EP3337787A4 (en) PYRAZOLO-CONDENSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
MA52623A (fr) Dérivés de dihydropyrazolo pyrazine carboxamide substitués
MX374348B (es) Formulacion adhesiva y metodos de plisado utilizando la misma.
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
PL3687996T3 (pl) Sole pochodnych pirolotriazyny użyteczne jako inhibitory tam
MX372740B (es) Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.
CO2022001860A2 (es) Derivados quinolina como inhibidores de proteína quinasa
EP3257857A4 (en) Substituted amino six-membered saturated heterocyclic fat used as long-acting dpp-iv inhibitor
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
EP3458066A4 (en) CONDENSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLE STIMULATORS
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
EP3551630A4 (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
MA52891A (fr) Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase
MA51285A (fr) Dérivés d'azaindole comme inhibiteurs de rho-kinase
PL4228755T3 (pl) Pochodne tetrazolowe jako inhibitory trpa1
MA41938A (fr) Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
CY1121709T1 (el) Παραγωγο τετραϋδροπυρρολο[3,4-d][1,3]θειαζινης ως αναστολεας της bace

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240702

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240702

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220